Top

Published in:

14-07-2021 | Glucocorticoid | Observational Research

Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids

Authors: Sadao Jinno, Kengo Akashi, Akira Onishi, Yoko Nose, Mai Yamashita, Jun Saegusa

Published in: Rheumatology International | Issue 8/2022

Abstract

We compared the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) with atovaquone for pneumocystis pneumonia (PCP) in patients with connective tissue diseases (CTDs) receiving high-dose glucocorticoids. Patients with CTDs aged ≥ 18 years who were treated with a prolonged course (≥ 4 weeks) of glucocorticoids (≥ 20 mg/day prednisone) in a Japanese tertiary center between 2013 and 2017 were included. The patients were categorized into two groups: TMP-SMX and atovaquone group. Adjusted cumulative incidence of PCP was compared between the two groups after propensity score weighting for differences in confounding factors. A total of 480 patients with a prolonged high-dose glucocorticoid treatment were identified. Out of 383 patients with TMP-SMX prophylaxis, 102 (26.8%) patients experienced adverse events leading to discontinuation within 4 weeks of initiation, while no patient in the atovaquone discontinued the therapy. Two hundred eighty-one patients received TMP-SMX, while 107 received atovaquone for PCP prophylaxis. During a total of 397.0 person-years, 7 PCP cases (2 in the TMP-SMX, 5 in the atovaquone) occurred with a mortality rate of 54.5%. After adjusting for differences in baseline characteristics, the adjusted cumulative incidence of PCP was similar between the two group (HR 0.97, 95% CI 0.19–5.09, p = 0.97). Prophylactic effects for PCP in CTDs patients receiving prolonged high-dose glucocorticoids were similar between TMP-SMX and atovaquone. Atovaquone was well-tolerated with no side effects.

Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180:369–376CrossRef

Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24:897–902. https://doi.org/10.1038/sj.bmt.1702004CrossRefPubMed

Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH (1998) Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother 32:1004–1007. https://doi.org/10.1345/aph.17464CrossRefPubMed

Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A (2012) Atovaquone versus trimethoprim-sulfamethoxazole as pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant 26:E184–E190. https://doi.org/10.1111/j.1399-0012.2012.01624.xCrossRefPubMed

Kimura M, Tanaka S, Ishikawa A, Endo H, Hirohata S, Kondo H (2008) Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int 28:673–676. https://doi.org/10.1007/s00296-007-0505-4CrossRefPubMed

Kitazawa T, Seo K, Yoshino Y, Asako K, Kikuchi H, Kono H et al (2019) Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother 25:351–354CrossRef

Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76. https://doi.org/10.1080/03602530902722679CrossRefPubMed

Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S (2009) Risk factors of pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 29:491–496. https://doi.org/10.1007/s00296-008-0721-6CrossRefPubMed

Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A et al (2011) An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128. https://doi.org/10.1164/rccm.2008-740STCrossRefPubMed

10.

Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77:644–649. https://doi.org/10.1136/annrheumdis-2017-211796CrossRefPubMed

11.

Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J (2003) Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 30:480–484PubMed

12.

Rodriguez M, Sifri CD, Fishman JA (2004) Failure of low-dose atovaquone prophylaxis against pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 38:e76–e78. https://doi.org/10.1086/383150CrossRefPubMed

13.

Sax PE, Komarow L, Finkelman MA, Grant PM, Andersen J, Scully E et al (2011) Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related pneumocystis jirovecii pneumonia. Clin Infect Dis 53:197–202. https://doi.org/10.1093/cid/cir335CrossRefPubMedPubMedCentral

14.

Smilack JD (1999) Trimethoprim-sulfamethoxazole. Mayo Clin Proc 74:730–734CrossRef

15.

Takenaka K, Komiya Y, Ota M, Yamazaki H, Nagasaka K (2013) A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against pneumocystis jiroveci pneumonia in rheumatic diseases. Mod Rheumatol 23:752–758. https://doi.org/10.1007/s10165-012-0730-xCrossRefPubMed

16.

Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K et al (2017) Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther 19:7–016. https://doi.org/10.1186/s13075-016-1206-8CrossRefPubMedPubMedCentral

17.

Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S (2011) Primary prophylaxis for pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41:497–502. https://doi.org/10.1016/j.semarthrit.2011.05.004CrossRefPubMed

18.

Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE (2018) Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 15:e1002685. https://doi.org/10.1371/journal.pmed.1002685CrossRefPubMedPubMedCentral

Title: Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids
Authors: Sadao Jinno
Kengo Akashi
Akira Onishi
Yoko Nose
Mai Yamashita
Jun Saegusa
Publication date: 14-07-2021
Publisher: Springer Berlin Heidelberg
Keywords: Glucocorticoid
Pneumonia
Atovaquone
Published in: Rheumatology International / Issue 8/2022
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04945-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2022

Focal lymphocytic sialadenitis and ectopic germinal centers in oral reactive lesions and primary Sjögren’s syndrome: a comparative study

Disease activity and subcutaneous nodules are associated to severe periodontitis in patients with rheumatoid arthritis

Clinical, radiologic and serologic profile of patients with interstitial pneumonia with autoimmune features: a cross-sectional study

Dropped head in systemic sclerosis: a case based review

Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility

Orbital myositis in systemic lupus erythematosus: a case-based review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials